1-4 of 4
George Simon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

Erick Riquelme, Milind Suraokar, Carmen Behrens, Heather Y. Lin, Luc Girard, Monique B. Nilsson, George Simon, Jing Wang, Kevin R. Coombes, J. Jack Lee, Waun Ki Hong, John Heymach, John D. Minna, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3849–3861.
https://doi.org/10.1158/1078-0432.CCR-13-1916
Published: 14 July 2014
View article titled, VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy
Open the PDF for VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer Wheler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil K. Kadam, Aejaz Nasir, Timothy R. Holzer, Funda Meric-Bernstam, Mayer Fishman, George Simon
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6582–6591.
https://doi.org/10.1158/1078-0432.CCR-11-0430
Published: 14 October 2011
View article titled, A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
Open the PDF for A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Scott J. Antonia, Noweeda Mirza, Ingo Fricke, Alberto Chiappori, Patricia Thompson, Nicholas Williams, Gerold Bepler, George Simon, William Janssen, Ji-Hyun Lee, Kerstin Menander, Sunil Chada, Dmitry I. Gabrilovich
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 878–887.
https://doi.org/10.1158/1078-0432.CCR-05-2013
Published: 07 February 2006
View article titled, Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Open the PDF for Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer in another window